The expanding role of immunotherapy

Cancer Treatment Reviews

Volumn 54, Issue , 2017, Pages 74-86

  Martin Liberal, Juan ^a   Ochoa de Olza, María ^a   Hierro, Cinta ^a   Gros, Alena ^a   Rodon, Jordi ^a   Tabernero, Josep ^a  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

Author keywords

Cell therapy; Checkpoint inhibitors; Co stimulatory agonists; Combination; Vaccines; Virus

Indexed keywords

ATEZOLIZUMAB; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SIPULEUCEL T; TALIMOGENE LAHERPAREPVEC; VIRUS VACCINE; CANCER VACCINE; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG EFFICACY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HELPER CELL; HODGKIN DISEASE; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; KIDNEY CARCINOMA; MALIGNANT NEOPLASM; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SYNOVIAL SARCOMA; TRANSITIONAL CELL CARCINOMA; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; CANCER VACCINES; CTLA-4 ANTIGEN; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85013230691     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2017.01.008     Document Type: Review

References (105)

1. [1] Nauts, H.C., Swift, W.E., Coley, B.L., The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res 6 (1946), 205–216.
2. [2] Morales, A., Eidinger, D., Bruce, A.W., Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:2 (1976), 180–183.
3. [3] Bindon, C., Czerniecki, M., Ruell, P., Edwards, A., McCarthy, W.H., Harris, R., et al. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects. Br J Cancer 47:1 (1983), 123–133.
4. [4] Kirkwood, J.M., Ernstoff, M.S., Davis, C.A., Reiss, M., Ferraresi, R., Rudnick, S.A., Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med 103:1 (1985), 32–36.
5. [5] http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm1193237.htm.
6. [6] Farkona, S., Diamandis, E.P., Blasutig, I.M., Cancer immunotherapy: the beginning of the end of cancer?. BMC Med, 14(1), 2016, 73.
7. [7] Lesterhuis, W.J., Haanen, J.B., Punt, C.J., Cancer immunotherapy–revisited. Nat Rev Drug Discov 10:8 (2011), 591–600.
8. [8] Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348:6230 (2015), 69–74.
9. [9] Lu, Y.C., Robbins, P.F., Cancer immunotherapy targeting neoantigens. Semin Immunol 28:1 (2016), 22–27.
10. [10] Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1 (2013), 1–10.
11. [11] Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature 480:7378 (2011), 480–489.
12. [12] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:4 (2012), 252–264.
13. [13] Motz, G.T., Coukos, G., Deciphering and reversing tumor immune suppression. Immunity 39:1 (2013), 61–73.
14. [14] Khalil, D.N., Smith, E.L., Brentjens, R.J., Wolchok, J.D., The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13:5 (2016), 273–290.
15. [15] Hathcock, K.S., Laszlo, G., Dickler, H.B., Bradshaw, J., Linsley, P., Hodes, R.J., Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 262:5135 (1993), 905–907.
16. [16] Freeman, G.J., Gribben, J.G., Boussiotis, V.A., Ng, J.W., Restivo, V.A., Lombard, L.A., et al. Cloning of B7–2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:5135 (1993), 909–911.
17. [17] Azuma, M., Ito, D., Yagita, H., Okumura, K., Phillips, J.H., Lanier, L.L., et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:6450 (1993), 76–79.
18. [18] Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348:6230 (2015), 56–61.
19. [19] Krummel, M.F., Allison, J.P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:2 (1995), 459–465.
20. [20] Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:5899 (2008), 271–275.
21. [21] Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J., Allison, J.P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206:8 (2009), 1717–1725.
22. [22] Weber, J.S., O'Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:36 (2008), 5950–5956.
23. [23] Yang, J.C., Hughes, M., Kammula, U., Royal, R., Sherry, R.M., Topalian, S.L., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:8 (2007), 825–830.
24. [24] van den Eertwegh, A.J., Versluis, J., van den Berg, H.P., Santegoets, S.J., van Moorselaar, R.J., van der Sluis, T.M., et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13:5 (2012), 509–517.
25. [25] Carthon, B.C., Wolchok, J.D., Yuan, J., Kamat, A., Ng Tang, D.S., Sun, J., et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16:10 (2010), 2861–2871.
26. [26] Hodi, F.S., Butler, M., Oble, D.A., Seiden, M.V., Haluska, F.G., Kruse, A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105:8 (2008), 3005–3010.
27. [27] Ribas, A., Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 37:5 (2010), 450–454.
28. [28] Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., van den Eertwegh, A.J., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:7 (2014), 700–712.
29. [29] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
30. [30] Robert, C., Thomas, L., Bondarenko, I., O'Day, S.M.D.J.W, Garbe, C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:26 (2011), 2517–2526.
31. [31] Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:17 (2015), 1889–1894.
32. [32] Greenwald, R.J., Freeman, G.J., Sharpe, A.H., The B7 family revisited. Annu Rev Immunol 23 (2005), 515–548.
33. [33] Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:7 (2000), 1027–1034.
34. [34] Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:8 (2002), 793–800.
35. [35] Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., et al. Blockade of B7–H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9:5 (2003), 562–567.
36. [36] Topalian, S.L., Taube, J.M., Anders, R.A., Pardoll, D.M., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:5 (2016), 275–287.
37. [37] Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:2 (2013), 134–144.
38. [38] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:26 (2012), 2443–2454.
39. [39] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med, 2014.
40. [40] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
41. [41] Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:4 (2015), 375–384.
42. [42] Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:8 (2015), 908–918.
43. [43] Ettinger, D.S., Wood, D.E., Akerley, W., Bazhenova, L.A., Borghaei, H., Camidge, D.R., et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J Natl Compr Canc Netw 14:3 (2016), 255–264.
44. [44] Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:19 (2015), 1803–1813.
45. [45] http://www.ascopost.com/News/40506.
46. [46] Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:26 (2012), 2455–2465.
47. [47] Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:7528 (2014), 558–562.
48. [48] Rosenberg, J.E., Hoffman-Censits, J., Powles, T., van der Heijden, M.S., Balar, A.V., Necchi, A., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:10031 (2016), 1909–1920.
49. [49] http://www.fdanews.com/articles/175440-fda-grants-breakthrough-designation-to-azs-durvalumab.
50. [50] Melero, I., Berman, D.M., Aznar, M.A., Korman, A.J., Pérez Gracia, J.L., Haanen, J., Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 15:8 (2015), 457–472.
51. [51] Huang, C.T., Workman, C.J., Flies, D., Pan, X., Marson, A.L., Zhou, G., et al. Role of LAG-3 in regulatory T cells. Immunity 21:4 (2004), 503–513.
52. [52] He, Y., Rivard, C.J., Rozeboom, L., Yu, H., Ellison, K., Kowalewski, A., et al. LAG-3, an important immune checkpoint in cancer. Cancer Sci, 2016.
53. [53] Johnston, R.J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26:6 (2014), 923–937.
54. [54] Lines, J.L., Pantazi, E., Mak, J., Sempere, L.F., Wang, L., O'Connell, S., et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 74:7 (2014), 1924–1932.
55. [55] Derré, L., Rivals, J.P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest 120:1 (2010), 157–167.
56. [56] Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., Brossay, L., Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 12:4 (2012), 239–252.
57. [57] Rezvani, K., Rouce, R.H., The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol, 6, 2015, 578.
58. [58] McCracken, M.N., Cha, A.C., Weissman, I.L., Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 “Don't Eat Me” signals. Clin Cancer Res 21:16 (2015), 3597–3601.
59. [59] Khalil, D.N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., et al. The new era of cancer immunotherapy: manipulating T-cell activity to overcome malignancy. Adv Cancer Res 128 (2015), 1–68.
60. [60] Molckovsky, A., Siu, L.L., First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol, 1, 2008, 20.
61. [61] Garber, K., Beyond ipilimumab: new approaches target the immunological synapse. J Natl Cancer Inst 103:14 (2011), 1079–1082.
62. [62] Mentlik James, A., Cohen, A.D., Campbell, K.S., Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol, 4, 2013, 481.
63. [63] Hirschhorn-Cymerman, D., Rizzuto, G.A., Merghoub, T., Cohen, A.D., Avogadri, F., Lesokhin, A.M., et al. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 206:5 (2009), 1103–1116.
64. [64] Curti, B.D., Kovacsovics-Bankowski, M., Morris, N., Walker, E., Chisholm, L., Floyd, K., et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 73:24 (2013), 7189–7198.
65. [65] van Kooten, C., Banchereau, J., CD40-CD40 ligand. J Leukoc Biol 67:1 (2000), 2–17.
66. [66] Schaer, D.A., Cohen, A.D., Wolchok, J.D., Anti-GITR antibodies–potential clinical applications for tumor immunotherapy. Curr Opin Investig Drugs 11:12 (2010), 1378–1386.
67. [67] Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:2 (2015), 205–214.
68. [68] Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., Dudley, M.E., Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:4 (2008), 299–308.
69. [69] Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:6230 (2015), 62–68.
70. [70] Restifo, N.P., Dudley, M.E., Rosenberg, S.A., Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:4 (2012), 269–281.
71. [71] Ikeda, H., T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. Int Immunol 28:7 (2016), 349–353.
72. [72] Rosenberg, S.A., Yang, J.C., Sherry, R.M., Kammula, U.S., Hughes, M.S., Phan, G.Q., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:13 (2011), 4550–4557.
73. [73] Vandenberk, L., Belmans, J., Van Woensel, M., Riva, M., Van Gool, S.W., Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol, 6, 2015, 663.
74. [74] Di Lorenzo, G., Buonerba, C., Kantoff, P.W., Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 8:9 (2011), 551–561.
75. [75] Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:5 (2010), 411–422.
76. [76] http://www.fdanews.com/articles/175370-adaptimmune-nabs-breakthrough-therapy-designation-for-ny-eso-t-cell-therapy.
77. [77] Morello, A., Sadelain, M., Adusumilli, P.S., Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 6:2 (2016), 133–146.
78. [78] Gross, G., Waks, T., Eshhar, Z., Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:24 (1989), 10024–10028.
79. [79] Jackson, H.J., Rafiq, S., Brentjens, R.J., Driving CAR T-cells forward. Nat Rev Clin Oncol 13:6 (2016), 370–383.
80. [80] Zhang, H., Ye, Z.L., Yuan, Z.G., Luo, Z.Q., Jin, H.J., Qian, Q.J., New strategies for the treatment of solid tumors with CAR-T cells. Int J Biol Sci 12:6 (2016), 718–729.
81. [81] Slaney, C.Y., von Scheidt, B., Davenport, A.J., Beavis, P., Westwood, J.A., Mardiana, S., et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin Cancer Res, 2016.
82. [82] Tran, E., Robbins, P.F., Lu, Y.C., Prickett, T.D., Gartner, J.J., Jia, L., et al. T-Cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375:23 (2016), 2255–2262.
83. [83] Brown, C.E., Alizadeh, D., Starr, R., Weng, L., Wagner, J.R., Naranjo, A., et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375:26 (2016), 2561–2569.
84. [84] Yaddanapudi, K., Mitchell, R.A., Eaton, J.W., Cancer vaccines: looking to the future. Oncoimmunology, 2(3), 2013, e23403.
85. [85] Whiteside, T.L., Demaria, S., Rodriguez-Ruiz, M.E., Zarour, H.M., Melero, I., Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res 22:8 (2016), 1845–1855.
86. [86] Hirayama, M., Nishimura, Y., The present status and future prospects of peptide-based cancer vaccines. Int Immunol 28:7 (2016), 319–328.
87. [87] Kono, K., Current status of cancer immunotherapy. J Stem Cells Regener Med 10:1 (2014), 8–13.
88. [88] Vermorken, J.B., Claessen, A.M., van Tinteren, H., Gall, H.E., Ezinga, R., Meijer, S., et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:9150 (1999), 345–350.
89. [89] Baars, A., Claessen, A.M., Wagstaff, J., Giaccone, G., Scheper, R.J., Meijer, S., et al. A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 86:8 (2002), 1230–1234.
90. [90] Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11:9 (2014), 509–524.
91. [91] Lichty, B.D., Breitbach, C.J., Stojdl, D.F., Bell, J.C., Going viral with cancer immunotherapy. Nat Rev Cancer 14:8 (2014), 559–567.
92. [92] Kaufman, H.L., Kohlhapp, F.J., Zloza, A., Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14:9 (2015), 642–662.
93. [93] Andtbacka, R.H., Kaufman, H.L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:25 (2015), 2780–2788.
94. [94] Barber, G.N., STING: infection, inflammation and cancer. Nat Rev Immunol 15:12 (2015), 760–770.
95. [95] Fu, J., Kanne, D.B., Leong, M., Glickman, L.H., McWhirter, S.M., Lemmens, E., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med, 7(283), 2015 283ra52.
96. [96] Munn, D.H., Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 18:2 (2006), 220–225.
97. [97] Vanneman, M., Dranoff, G., Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:4 (2012), 237–251.
98. [98] Kahn, M., Can we safely target the WNT pathway?. Nat Rev Drug Discov 13:7 (2014), 513–532.
99. [99] Chiappinelli, K.B., Zahnow, C.A., Ahuja, N., Baylin, S.B., Combining epigenetic and immunotherapy to combat cancer. Cancer Res 76:7 (2016), 1683–1689.
100. [100] Weiner, L.M., Surana, R., Wang, S., Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:5 (2010), 317–327.
101. [101] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 2015.
102. [102] Ribas, A., Hodi, F.S., Callahan, M., Konto, C., Wolchok, J., Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 368:14 (2013), 1365–1366.
103. [103] Rini, B.I., Stein, M., Shannon, P., Eddy, S., Tyler, A., Stephenson, J.J., et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 117:4 (2011), 758–767.
104. [104] Anderson, A.C., Joller, N., Kuchroo, V.K., Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44:5 (2016), 989–1004.
105. [105] Morrissey, K.M., Yuraszeck, T.M., Li, C.C., Zhang, Y., Kasichayanula, S., Immunotherapy and novel combinations in oncology: current landscape, challenges, and opportunities. Clin Transl Sci 9:2 (2016), 89–104.